NYSE$BIO
Bio-Rad Laboratories Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported a decrease in net sales and a net loss due to changes in the fair market value of equity securities.
Bio-Rad reported Q4 2021 net sales of $732.8 million, a 7.2% decrease compared to Q4 2020. The company experienced a net loss of $1,573.7 million, or $52.59 per share, compared to a net income of $839.1 million, or $27.81 per share in the same period last year. COVID-related revenue was approximately $46 million, versus $132 million in 2020.
- Net sales decreased by 7.2% compared to Q4 2020.
- Life Science segment net sales decreased by 23.8% compared to the same period in 2020, primarily due to lower qPCR product revenue.
- Clinical Diagnostics segment net sales increased by 12.6% compared to the same period in 2020, driven by recovery of routine testing.
- Net loss was $1,573.7 million, or $52.59 per share, compared to net income of $839.1 million, or $27.81 per share in 2020.
Headline financials
Revenue & EPS history
Bio-Rad · Revenue · Quarterly
$733M
Revenue by segment
Bio-Rad · $732M total across 2 segments · Q4 2021
- Clinical Diagnostics Group$405M+12.6%55.4%
- Life Science Group$327M-23.8%44.6%
Forward guidance
Bio-Rad anticipates non-GAAP currency-neutral revenue growth of approximately 1.0 to 2.0 percent and an estimated non-GAAP operating margin of approximately 19.0 percent for the full year 2022.
Tailwinds
- Anticipates another year of progress in 2022.
- Building on the operating efficiencies achieved in 2021.
- Well positioned to build on recent momentum.
- Continuing to return to normalcy.
- Executing growth strategies.
Headwinds
- Regional COVID upswings still persist.
- COVID upswings can impact supply chain.
- COVID upswings can impact order flow.
- Future gains or losses associated with certain legal matters are difficult to predict.
- Acquisitions and restructuring activities are difficult to estimate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.9%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+0.3%
Avg return
30 days after
54%
37 / 68 earnings
Positive
+20.0%
Q3 2017
Best reaction
-16.9%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.6% | -7.5% | +11.3% | |
| Q4 2025 | -12.3% | -7.4% | -10.1% | |
| Q3 2025 | -4.7% | -2.7% | +1.7% | |
| Q1 2025 | -1.9% | -3.3% | -5.6% | |
| Q4 2024 | -9.5% | -7.4% | -16.9% | |
| Q3 2024 | +8.0% | +11.2% | +2.7% | |
| Q2 2024 | -0.7% | -3.4% | -0.3% | |
| Q1 2024 | -4.9% | +0.0% | +2.5% | |
| Q4 2023 | +3.8% | +4.8% | +1.7% | |
| Q3 2023 | -6.7% | -5.1% | +7.3% | |
| Q2 2023 | -0.9% | -0.2% | -2.3% | |
| Q1 2023 | -16.9% | -20.9% | -19.7% | |
| Q4 2022 | +4.9% | +1.7% | +2.0% | |
| Q3 2022 | -10.1% | -9.1% | +2.5% | |
| Q2 2022 | +3.0% | +0.2% | -9.4% | |
| Q1 2022 | +2.2% | -0.0% | +9.2% | |
| Q4 2021 | -1.2% | -3.1% | -16.8% | |
| Q3 2021 | +3.9% | +1.9% | -1.9% | |
| Q2 2021 | +4.7% | +5.6% | +12.2% | |
| Q1 2021 | -2.9% | -7.8% | -7.2% | |
| Q4 2020 | +4.8% | +2.8% | -11.4% | |
| Q3 2020 | +4.8% | +7.5% | -4.4% | |
| Q2 2020 | -1.1% | -0.7% | -6.0% | |
| Q1 2020 | +3.9% | +6.2% | +2.1% | |
| Q4 2019 | +7.5% | +8.5% | -7.4% | |
| Q3 2019 | +2.3% | +1.1% | +7.2% | |
| Q2 2019 | +6.7% | +1.9% | +7.2% | |
| Q1 2019 | +3.9% | -0.5% | -2.6% | |
| Q4 2018 | +15.8% | +14.0% | +11.6% | |
| Q3 2018 | -1.1% | +2.2% | +0.6% | |
| Q2 2018 | +0.3% | +1.4% | +0.4% | |
| Q1 2018 | +8.3% | +11.9% | +16.6% | |
| Q4 2017 | +4.7% | +2.0% | -3.0% | |
| Q3 2017 | +20.0% | +20.4% | +23.4% | |
| Q2 2017 | -4.7% | -7.4% | -8.2% | |
| Q1 2017 | -0.8% | +1.4% | +3.8% | |
| Q4 2016 | +0.1% | +1.5% | +4.6% | |
| Q3 2016 | +4.8% | +4.2% | +10.4% | |
| Q2 2016 | +6.1% | +5.2% | +3.5% | |
| Q1 2016 | -0.5% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -0.6% | — | — | |
| Q2 2015 | -0.2% | — | — | |
| Q1 2015 | +4.3% | — | — | |
| Q4 2014 | +7.8% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +5.0% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q3 2013 | -0.9% | — | — | |
| Q2 2013 | -2.5% | — | — | |
| Q1 2013 | -1.0% | — | — | |
| Q4 2012 | +5.3% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | +7.3% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2011 | -0.4% | — | — | |
| Q2 2011 | -0.4% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q1 2011 | +1.0% | — | — | |
| Q1 2010 | +1.0% | — | — | |
| Q4 2008 | -1.3% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q3 2010 | +0.4% | — | — | |
| Q3 2009 | +0.4% | — | — | |
| Q4 2009 | +0.3% | — | — | |
| Q2 2009 | +0.3% | — | — | |
| Q2 2010 | +0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro